Therefore, the potential for asciminib combined with LY3295668 to improve the survival of CML patients, particularly those resistant to ABL TKIs and have experienced treatment failure, is noteworthy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.